Key result
Global hypertension review highlights projected ~29% adult prevalence by 2025 across clinical trials.
Why the study?
Hypertension remains poorly treated in almost all countries despite increasing availability of effective medications, prompting an examination of the role of randomized controlled trials in hypertension management.
Answers are grounded in this paper and cite their sources.
RCT evidence on hypertension; extends prior data but leaves optimal targets open for further trials.
C urrent projections predict that, by the year 2025, 29.2% of the adult population worldwide will have hypertension, a total of 1.56 billion people. 1 Such figures are hard to visualize, as are the billions of dollars being spent on the Iraqi invasion.Enough to say that hypertension is now and has long been the most common risk for the most common causes of death in all but the most primitive populations in the world.Despite such knowledge, the disease is poorly treated in almost all countries including the United States despite the increasing availability of effective and innocuous medications.2 A detailed analysis of the reasons responsible for our failure to control most hypertension is not the aim of this Hypertension Highlight, but rather the place of randomized, controlled trials (RCTs) in coming to where we are and where we ought to be.
No takes yet. Share an insight, caveat, or question.
Norman M. Kaplan (2006) conducted a review in Hypertension. Antihypertensive therapy evaluated in randomized controlled trials was evaluated. Randomized controlled trials for hypertension are reviewed against projections that 29.2% of adults worldwide will have hypertension by 2025.
Synapse has enriched 10 related papers. Consider them for comparative context: